Stellar Blade, the well-received sci-fi action-adventure from developer Shift Up, is targeting a 2025 release on PC, and the studio says it expects sales to exceed those seen on console.

Korean game developer Shift Up has announced that popular action sci-fi game Stellar Blade is intended to come to PC sometime in 2025. Having launched exclusively on PlayStation 5, the game has ...

Please verify your email address. Stellar Blade ends 2024 strong with NieR: Automata crossover on November 20 & photo mode launch. The crossover will feature new outfits for EVE and specific items ...

Stellar Blade's next DLC is a "fantastic" collaboration with Nier: Automata and it's set to release on 20th November. In a post published on the PlayStation Blog, Shift Up technical director and ...

South Korean developer Shift Up is planning to release Stellar Blade on PC in 2025, according to its latest earnings report. The sci-fi RPG launched earlier this year as a PS5-exclusive ...

All this means that big data technologies present a major opportunity for solution providers, MSPs and strategic service providers. As part of CRN’s Stellar Startups for 2024, here are 10 big ...

London, UK 17 October 2024 - Meridian 2024, Stellar Development Foundation’s annual conference, wrapped up three days of sessions highlighting the growth in the Stellar network’s ecosystem and ...

Some startups are providing security for new AI systems and machine learning models while others offer tools for managing the huge volumes of data AI/ML ... part of CRN’s Stellar Startups ...

Please verify your email address. Stellar Blade's 1.008 update adds PlayStation 5 Pro support. New High Frame Rate mode minimizes input lag for enhanced performance. Upcoming DLC includes Stellar ...

Shift Up has released Stellar Blade update 1.008 today, which is a major patch for the game that introduces PS5 Pro support ahead of the console’s release on November 7. One of the biggest ...

After combining data from direct observations of Betelgeuse with advanced computer models that simulate the star's activity, the team concluded that Betelbuddy is by far the most likely explanation.

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...